<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03013946</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-NZK-0115/ass</org_study_id>
    <secondary_id>2016‐000399‐28</secondary_id>
    <nct_id>NCT03013946</nct_id>
  </id_info>
  <brief_title>Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib</brief_title>
  <acronym>PREPARE</acronym>
  <official_title>A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to determine the effect of a 24-week concomitant
      coaching on patient reported outcomes of patients receiving standard treatment for mRCC with
      sunitinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of our study is to define the benefit of proactive coaching in mRCC, when compared
      to a reactive approach, which is considered the standard of care.

      Patients in the Coaching Arm A will be trained continuously at personal interactions of coach
      and patient (Face-to Face meetings as well as telephone contacts). The patient is educated on
      nature and severity of treatment emergent Adverse events (TEAE) of the Sunitinib-Therapy.

      Quality of Life (QoL) is assessed during sunitinib treatment in both arms (Arm A Coaching and
      Arm B non Coaching).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QoL assessment during sunitinib treatment: questionnaire</measure>
    <time_frame>24 weeks from randomization</time_frame>
    <description>Rate of responders to concomitant coaching assessed by the (Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)) FKSI-15 questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) according to RECIST 1.1 criteria</measure>
    <time_frame>up to one year from randomization</time_frame>
    <description>Objective Response Rate (ORR) according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 36 months from randomization</time_frame>
    <description>Overall Survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>up to 36 months from randomization</time_frame>
    <description>progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment (coaching and cancer treatment)</measure>
    <time_frame>Coaching: up to 24 weeks from randomization / cancer treatment: up to 36 months from randomization</time_frame>
    <description>Duration of treatment (coaching and cancer treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dose density of sunitinib</measure>
    <time_frame>24 weeks from randomization</time_frame>
    <description>dose density of sunitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients receiving treatment beyond progression</measure>
    <time_frame>up to 36 months from randomization</time_frame>
    <description>Rate of patients receiving treatment beyond progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Further cancer treatment</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Further cancer treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent therapy (TFST)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Time to first subsequent therapy (TFST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient adherence / treatment discontinuation due to Adverse drug reactions (ADRs) / Serious adverse events (SAEs):</measure>
    <time_frame>24 weeks from randomization</time_frame>
    <description>% of patients with treatment discontinuation due to specific ADRs (e.g. hand-foot syndrome, diarrhea, stomatitis, fatigue, hypertension)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Events according to CTC 4.03:</measure>
    <time_frame>24 weeks from randomization</time_frame>
    <description>Frequency/incidence, severity, percentage reduction, time-to-event of ADRs, AEs and specific TEAEs (e.g. hand-foot syndrome, diarrhea, stomatitis, fatigue, hypertension)
change of grade 3/4 ADRs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of comorbidities</measure>
    <time_frame>at inclusion</time_frame>
    <description>Charlson Comorbidity Index (CCI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Renal Cell Carcinoma, Metastatic</condition>
  <condition>Renal Cell Cancer, Recurrent</condition>
  <arm_group>
    <arm_group_label>Arm A (Coaching)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant coaching (24 weeks) Pro-active TEAE (Treatment emergent adverse events) management Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Re-activeTEAE management (SOC) Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Concomitant coaching</intervention_name>
    <description>The corner stones of the pro-active coaching are as follows:
Patient education:
Information on nature and severity of treatment emergent AEs
information about remedies for TEAEs
propagation and explanation of tests and treatment decisions
Patient instruction on self-care and preventive measures
Preemptive AE treatment strategies
Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach</description>
    <arm_group_label>Arm A (Coaching)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent and any locally-required authorization (EU Data Privacy
             Directive in the EU) obtained from the subject prior to performing any
             protocol-related procedures, including screening evaluations

          2. Age ≥ 18 years at time of study entry

          3. Advanced or metastatic renal cell carcinoma, not amendable to surgery with curative
             intent, rendering the patient eligible for Tyrosin Kinase Inhibitor (TKI) treatment
             with sunitinib

          4. Intended first-line treatment with sunitinib

          5. Documented progressive disease within 6 months prior to study inclusion

          6. Patients with measurable disease (at least one uni-dimensionally measurable target
             lesion by CT-scan or MRI) according to modified Response Evaluation Criteria in Solid
             Tumors (RECIST 1.1) as well as non-measurable disease are eligible.

          7. Prior radiotherapy and surgery are allowed if completed 4 weeks (for minor surgery and
             palliative radiotherapy for bone pain: 2 weeks) prior to start of treatment and
             patient recovered from toxic effects.

          8. Female subjects must either be of non-reproductive potential (ie, post-menopausal by
             history: ≥60 years old and no menses for ≥1 year without an alternative medical cause;
             OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of
             bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.

          9. Subject is willing to receive additional concomitant coaching and able to comply with
             the QoL/PRO (patient-reported outcome) assessments specified in the protocol for the
             duration of the study including scheduled visits, examinations and follow up.

        Exclusion Criteria:

          1. Any other anti-cancer treatment aside of sunitinib for mRCC (except palliative
             radiotherapy)

          2. Previous malignancy (other than mRCC) which either progresses or requires active
             treatment.

             Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a
             or T1b prostate carcinoma, or superficial bladder tumor [Ta, Tis and T1].

          3. CNS metastases, unless local therapy has been completed for at least 3 month and
             patient does not require the use of steroids.

          4. Chronic liver disease with Child-Pugh B or C score

          5. Female subjects who are pregnant, breast-feeding or male or female patients of
             reproductive potential who are not employing an effective method of birth control
             (failure rate of less than 1% per year)

          6. Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the concomitant coaching or QoL assessments or interpretation of patient
             safety or study results

          7. Participation in another clinical study with an investigational product during the
             last 30 days before inclusion

          8. Any previous treatment with a tyrosine kinase inhibitor for metastatic disease.
             Adjuvant or neoadjuvant therapy for localized disease is permitted, provided that
             relapse occurred at least 6 months after last exposure

          9. Previous enrollment or randomization in the present study (does not include screening
             failure).

         10. Involvement in the planning and/or conduct of the study (applies to both Pfizer staff
             and/or staff of sponsor and study site)

         11. Patient who might be affiliated or otherwise dependent on the sponsor, site or the
             investigator

         12. Patient who has been incarcerated or involuntarily institutionalized by court order or
             by the authorities [§ 40 Abs. 1 S. 3 Nr. 4 AMG].

         13. Patients who are unable to consent because they do not understand the nature,
             significance and implications of the clinical trial and therefore cannot form a
             rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viktor Grünwald, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aysun Karatas, Dr.</last_name>
    <phone>+49 30 8145 344</phone>
    <phone_ext>31</phone_ext>
    <email>aysun.karatas@aio-studien-ggmbh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Markus Detzner</last_name>
    <phone>+49 30 8145344</phone>
    <phone_ext>52</phone_ext>
    <email>Markus.Detzner@aio-studien-ggmbh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum St. Marien Amberg</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludwig Fischer von Weikersthal, Dr.med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologisches Versorgungszentrum</name>
      <address>
        <city>Berlin</city>
        <zip>10407</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fritz Maiwirth, Dr.med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike de Wit, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BAG Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Jacobasch, Dr.med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. med. Johannes Mohm Dr. med. Gabriele Prange Krex Fachärzte für Innere Medizin Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johannes Mohm, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Wirth, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ für Hämato/Onkologie Essen gGmbH</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulla Frfr. von Verschuer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Onkologische Kooperation Harz</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark-Oliver Zahn, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Metz, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Ivanyi, Dr.</last_name>
      <phone>+49 511 532</phone>
      <phone_ext>2301</phone_ext>
      <email>Ivanyi.Philipp@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urologie Herzberg</name>
      <address>
        <city>Herzberg</city>
        <zip>37412</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thorsten Werner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IDGGQ Institut für medizinische Dokumentation, Gutachtenerstellung, Gesundheitsförderung u. Qualitätssicherung</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Hansen, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tagesklinik Landshut Hämatologie, Onkologie Palliativmedizin</name>
      <address>
        <city>Landshut</city>
        <zip>84028</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ursula Vehling-Kaiser, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie u. Onkologie PD Dr. Jan Schröder</name>
      <address>
        <city>Mühlheim</city>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Schröder, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Bögemann, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg 5. Medizinische Klinik</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marinela Augustin, Dr.med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medius KLINIKEN gGmbH</name>
      <address>
        <city>Ostfildern</city>
        <zip>73760</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serdar Deger, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wissenschaftskontor Nord GmbH &amp; Co KG</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hübner, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Singen</city>
        <zip>78224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Banhardt, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Kloster Paradiese GbR/Onkologiezentrum Soest</name>
      <address>
        <city>Soest</city>
        <zip>59494</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anke Wortmann, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2017</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

